The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus

Clinical Infectious Diseases

Volumn 27, Issue 5, 1998, Pages 1259-1265

  Lautenbach, Ebbing ^b   Schuster, Mindy G ^b   Bilker, Warren B ^b   Brennan, Patrick J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; DRUG EFFICACY; DRUG RESPONSE; ENTEROCOCCUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

EID: 0032458951     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515002     Document Type: Article

References (26)

1. Schaberg DR. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91(suppl 3B):72S-5S.
2. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci [letter]. Lancet 1988; 1:57-8.
3. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR 1993; 42: 597-9.
4. Dominguez ER, Diaz A, Greene JN, Sandin RL. Successful treatment of vancomycin-resistant enterococcal bacteremia using combination antibiotic therapy [abstract no 169]. In: Program and abstracts of the 34th Annual Meeting of the Infectious Diseases Society of America (New Orleans). Washington, DC: Infectious Diseases Society of America, 1996:891.
5. Caron F, Carbon C, Butmann L. Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 1991; 164:888-93.
6. Shlaes DM, Etter L, Gutmann L. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother 1991; 35: 776-9.
7. Whitman MS, Pitsakis PG, Zausner A, et al. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1993; 37:2069-73.
8. Papanicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996; 23:760-6.
9. Perri MB, Chow JW, Zervos MJ. In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1993; 17:151-5.
10. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22: 663-70.
11. Marder HP, Keyser FH. Transferable plasmids mediating multiple antibiotic resistance in Streptococcus faecalis subspecies liguifaciens. Antimicrob Agents Chemother 1977; 12:261-70.
12. Moellering RC. Chloramphenicol: an option for vancomycin-resistant enterococci? J Crit Illness 1996; 11:705.
13. Hardalo C, Rigsby M, Chen L. Chloramphenicol treatment of resistant Enterococcus faecium infections [abstract no 110], In: Program and Abstracts of the 31st Annual Meeting of the Infectious Diseases Society of America (New Orleans). Washington, DC: Infectious Diseases Society of America, 1993:20-A.
14. Norris AH, Reilly JP, Edelstein PH, Brennan PJ, Schuster MG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995; 20:1137-44.
15. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin-resistance and predictors of mortality [abstract no 49]. Infect Control Hosp Epidemiol 1997; 18:28.
16. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995; 20:296-301.
17. Noskin GA, Till M, Patterson BK, Clarke JT, Warren JR. High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis 1991; 164:1212-5.
18. Weinstein MP, Murphy JR, Reller LB, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis 1983; 5:54-70.
19. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90.
20. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
21. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91(suppl 3B):86S-9S.
22. Edmond MB, Ober JF, Sawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-9.
23. Stosor V, Peterson LR, Postelnick M, Noskin GA. Therapy of vancomycin resistant Enterococcus faecium sepsis: a novel strategy [abstract no 170]. In: Program and abstracts of the 34th Annual Meeting of the Infectious Diseases Society of America (New Orleans) Washington, DC: Infectious Diseases Society of America, 1996:891.
24. Chow JW, Donabedian SM, Zervos MJ. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia [letter]. Clin Infect Dis 1997; 24:90-1.
25. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172:993-1000.
26. Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996; 156:2579-84.